Viasys Healthcare spun off from Thermo Electron
This article was originally published in Clinica
Viasys Healthcare has been spun off from parent company Thermo Electron as a dividend to shareholders. Thermo has distributed 0.1461 shares of Viasys common stock for each share of Thermo Electron to shareholders of Thermo, which no longer owns any Viasys shares.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.